Evidence map›Paper›PMID 42165327›Full record

Trial reportmAbs2026

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.

Dirk van Lier, Louis Mourisse, Hákon Hollander, Karine Santos, Andreas Bergmann, Antonius Eduard van Herwaarden, Matthijs Kox, Peter Pickkers

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06331884 (Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of AK1967), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06331884 phase1completednot on this map

Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of AK1967 (Procizumab) in Healthy Male Volunteers

TypeinterventionalSponsor4TEEN4 Pharmaceuticals GmbHRan2024 to 2024Enrolled24ConditionsSafety and Tolerability, Healthy VolunteersArmsAK1967 (Procizumab), Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dirk van LierDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-9176-4852
Louis MourisseDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.
Hákon HollanderDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.
Karine Santos4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.
Andreas Bergmann4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.
Antonius Eduard van HerwaardenDepartment of Clinical Chemistry, Radboud University Medical Center, Nijmegen, The Netherlands.
Matthijs KoxDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.
Peter PickkersDepartment of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dipeptidyl peptidase 3 (DPP3), an aminopeptidase that degrades several key cardiovascular mediators, may induce and exacerbate hemodynamic instability during cardiogenic shock. Procizumab (PCZ) is a first-in-class humanized monoclonal antibody that inhibits DPP3 activity. In preclinical shock models, PCZ increased angiotensin metabolite levels, improved cardiovascular function, and increased survival. Here, results are presented for a first-in-human Phase 1 trial (NCT06331884) that evaluated the safety, tolerability, and pharmacokinetics and pharmacodynamics of PCZ. Twenty-four healthy male volunteers were enrolled in a randomized, double-blind, placebo-controlled Phase 1 trial. Participants (

Indexed as

Antibodies, Monoclonal, HumanizedDipeptidyl-Peptidases and Tripeptidyl-PeptidasesAdultDouble-Blind MethodHumansMaleMiddle AgedYoung AdultAntibodies, Monoclonal, HumanizedDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDPP3 protein, humanDipeptidyl peptidase 3Phase-1 trialProcizumab

Identifiers

PMID42165327
PMCPMC13196652

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.